PHA-739358 in Treating Patients With Chronic Myelogenous Leukemia That Relapsed After Imatinib Mesylate or c-ABL Therapy

DISEASE CHARACTERISTICS: * Diagnosis of chronic myelogenous leukemia confirmed by bone marrow biopsy * Chronic, accelerated, or blastic phase disease * May have T315I mutation in BCR-ABL kinase * Relapsed after prior imatinib mesylate or c-ABL therapy * No CNS leukemia PATIENT CHARACTERISTICS: * ECOG performance status 0-2 * Blood pressure ≤ 140/90 mm Hg (with or without hypertension treatment for ≥ 1 week) * Transaminases ≤ 2.5 times upper limit of normal (ULN) * Bilirubin ≤ 1.5 times ULN * Creatinine ≤ 1.5 times ULN * No known history of HIV infection * No active uncontrolled infection * No grade 3 or 4 bleeding * LVEF ≥ 45% by MUGA or ≥ 40% by transthoracic echocardiography * No medical or psychiatric condition or laboratory abnormalities that would limit study compliance or increase risk during study participation * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception during and for 90 (female) or 180 (male) days after completion of study treatment * No significant cardiovascular disease (i.e., uncontrolled arrhythmias or unstable angina) within the past 6 months * No major thromboembolic event within the past 6 months, including any of the following: * Myocardial infarction * Stroke * Transient ischemic attack * Pulmonary embolism * Noncatheter-related deep-vein thrombosis PRIOR CONCURRENT THERAPY: * Recovered from all acute toxic effects (excluding alopecia) of prior therapy * More than 2 weeks since prior chemoimmunotherapy * Hydroxyurea must be discontinued 1 day prior to study therapy * More than 4 weeks since prior major surgery * No other concurrent approved or investigational anticancer treatment, including chemotherapy, biologic response modifiers, hormones, or immunotherapy * No other concurrent investigational drugs * No concurrent participation in another treatment clinical trial